These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6917760)

  • 1. Quality assurance vs cost containment: "damned if you do, damned if you don't".
    Schron SR
    AANNT J; 1982 Apr; 9(2):13-23. PubMed ID: 6917760
    [No Abstract]   [Full Text] [Related]  

  • 2. The politics of health cost containment: end-stage renal disease.
    Rettig RA
    Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
    [No Abstract]   [Full Text] [Related]  

  • 3. Justice and cost-containment in end-stage renal disease.
    Johnstone BV
    J Contemp Health Law Policy; 1987; 3():65-84. PubMed ID: 10301637
    [No Abstract]   [Full Text] [Related]  

  • 4. Working on costs. And Baldrige program is a plus for quality--yanking funding is just plain dumb.
    McLaughlin N
    Mod Healthc; 2011 Nov; 41(45):20. PubMed ID: 22106776
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost functions for dialysis facilities and the quality of dialysis.
    Escarce JJ; Feldman HI
    Health Serv Res; 1999 Feb; 33(6):1563-6. PubMed ID: 10029497
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of renal failure in the light of increasingly limited resources.
    Wing AJ
    Contrib Nephrol; 1985; 44():260-74. PubMed ID: 3987290
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality assurance and cost containment in teaching hospitals: implications for a period of economic restraint.
    Everett GD
    QRB Qual Rev Bull; 1985 Feb; 11(2):42-6. PubMed ID: 3920600
    [No Abstract]   [Full Text] [Related]  

  • 8. Attending to quality assurance, economics, and the nursing shortage.
    Hull A
    Nephrol News Issues; 1990 Apr; 4(4):18, 63, 68. PubMed ID: 2333117
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality assurance and dialysis services.
    Lancet; 1990 Nov; 336(8724):1160-1. PubMed ID: 1978031
    [No Abstract]   [Full Text] [Related]  

  • 10. Suggestions for health care cost control: an alternative point of view.
    van Linda B
    Conn Med; 1992 May; 56(5):257. PubMed ID: 1611898
    [No Abstract]   [Full Text] [Related]  

  • 11. Provider-patient relations and treatment choice in the era of fiscal incentives: the case of the end-stage renal disease program.
    Bovbjerg RR; Held PJ; Diamond LH
    Milbank Q; 1987; 65(2):177-202. PubMed ID: 3614141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal transplantation without dialysis: better results at a lower cost?
    John GT; Viswanathan S
    Natl Med J India; 2001; 14(4):224. PubMed ID: 11547530
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs.
    Kleophas W; Karaboyas A; Li Y; Bommer J; Reichel H; Walter A; Icks A; Rump LC; Pisoni RL; Robinson BM; Port FK
    Kidney Int; 2013 Sep; 84(3):578-84. PubMed ID: 23636176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is expected of a medical director in the Centers for Medicare and Medicaid Services Conditions of Coverage?
    Wish JB
    Blood Purif; 2011; 31(1-3):61-5. PubMed ID: 21228568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of clinical dialysis--a historical perspective.
    Attrill E; Johnson HK
    Semin Nephrol; 2000 Nov; 20(6):523-5. PubMed ID: 11111853
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicare Program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final Rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2015 Nov; 80(215):68967-9077. PubMed ID: 26552112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marginal improvement. Don't expect pay-for-performance programs to solve quality, cost problems.
    Raube K
    Mod Healthc; 2009 Jun; 39(25):25. PubMed ID: 19579674
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A break-even point in the ESRD program.
    Mayer RL
    Nephrol News Issues; 1989 Nov; 3(11):20-1. PubMed ID: 2594106
    [No Abstract]   [Full Text] [Related]  

  • 20. Foreword: health care reform in the United States--the Presidential Task Force.
    Gostin LO
    Am J Law Med; 1993; 19(1-2):1-20. PubMed ID: 8368198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.